Pharmacokinetics and safety of oral almotriptan in healthy male volunteers

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 7, 2004, Pages 303-311

  McEwen, J ^a   Salva, M ^b   Jansat, J M ^b   Cabarrocas, X ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Research Centre ^*  (Spain)

Author keywords

5 HT1B 1D agonist; Almotriptan; Migraine; Serotonin

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; DRUG METABOLITE; PLACEBO; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; FLUSHING; GENDER; HEADACHE; HEARTBURN; HEMATOMA; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; LOW BACK PAIN; MALE; MIGRAINE; MUSCLE CRAMP; NAUSEA; NECK PAIN; NORMAL HUMAN; OTITIS MEDIA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOFT TISSUE INJURY; SOMNOLENCE; SORE THROAT; SWEAT GLAND DISEASE; THORAX PAIN; TOOTH PAIN; URINARY EXCRETION; VOLUNTEER; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; HUMANS; INDOLES; MALE; MIDDLE AGED; TRYPTAMINES;

EID: 6444226582     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.412     Document Type: Article

References (16)

1. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994; 44(suppl 4): S17-S23.
2. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol Clin 1997; 15: 1-13.
3. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann N Y Acad Sci 1990; 600: 587-598.
4. Humphrey PP. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991; 238(suppl 1): S38-S44.
5. Goadsby PJ. Serotonin receptors and the acute attack of migraine. Clin Neurosci 1998; 5: 18-23.
6. Goadsby PJ, Hoskin KL. Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT1B/1D receptor: a central action in migraine. Ann Neurol 1998; 43: 711-718.
7. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998; 55: 889-922.
8. Bou J, Domenech T, Puig J, et al. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000; 410: 33-41.
9. Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalgia 2001; 21: 804-812.
10. Gras J, Bou J, Llenas J, Fernandez AG, Palacios JM. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 2000; 410: 43-51.
11. Gras J, Cardelus I, Llenas J, Palacios JM. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine. Eur J Pharmacol 2000; 410: 53-59.
12. Salva M, Jansat JM, Martinez-Tobed A, Palacios JM. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Disp 2003; 31: 404-411.
13. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000; 67: 498-503.
14. Fleishaker JC, Ryan KK, Carel BJ, Azie NE. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol 2001; 41: 217-223.
15. Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 2001; 51: 437-441.
16. Jansat JM, Costa J, Salva P, Fernandez FJ, Martinez-Tobed A. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J Clin Pharmacol 2002; 42: 1303-1310.